• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:辛栋轶,于旭红,方芳,辛学俊,谢觉醒,朱齐兵,林峰,蒋能,段达荣,丁如良,章志坚.头孢哌酮钠舒巴坦钠微泵3 h静脉给药的临床疗效和经济学评价[J].药学研究,2020,39(10):609-613,620[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2636次   下载 2943次 本文二维码信息
码上扫一扫!
头孢哌酮钠舒巴坦钠微泵3 h静脉给药的临床疗效和经济学评价
辛栋轶1,于旭红2,方芳3,辛学俊4,谢觉醒1,朱齐兵4,林峰1,蒋能5,段达荣6,丁如良1,章志坚1
字体:加大+|默认|缩小-
(1.台州市第一人民医院外科,浙江 台州 318020;2.中国人民解放军第三○五医院临床药学室,北京 100017;3.重庆市中医院临床药学室,重庆 400021;4.台州市第一人民医院临床药学室,浙江 台州 318020;5.台州市第一人民医院眼科,浙江 台州 318020;6.台州市第一人民医院中心实验室,浙江 台州 318020)
摘要:
目的 探索头孢哌酮钠舒巴坦钠(舒普深)同一剂量、不同给药方案的抗菌强度差异。方法 计算每次静脉滴注0.5 h完成与延时给药(2 h、3 h)的头孢哌酮钠血药浓度(C)和药动学药效学(PK/PD)参数(%T>MIC),评价临床疗效和药物经济学成本。结果 ①3 h终点药物浓度:同一剂量(1 g),延时2 h和3 h组是0.5 h组的140.3%(40.0/28.5)、179.2%(51.1/28.5)。②抗菌强度(%T>MIC)增幅:a.同剂量,不同给药间隔,每次均静滴0.5 h : q8h、 q6h组较q12 h组增幅50% 、100% ;b.同剂量,不同给药间隔,不同给药时间:q12h组:延时(2 h、3 h),较0.5 h、增幅为14%;11.7% ;q8h组:增幅为13.8%、20.9%;c. (q6h)(延时2h、3h)比(q12 h、0.5 h )增幅分别 为207%、234.9%;d.同一日剂量(4.0 g)(%T>MIC)值:(1.0 g, q6h,延时2h、3h),较(2.0g, q12h ,0.5 h)增加50%~70%。③达同一抗菌强度,增加给药次数,辅助延时给药,医药成本下降1/3:(1.0 g,g8h,延时2.0 h)(%T>MIC)=61.2,较(2 g, q12 h ,0.5 h) 日剂量4.0 g(%T>MIC=60.0),减少日剂量1/3。结论 舒普深增加给药次数,联合延时给药3 h,提高抗菌强度,节约医药成本,为重症感染患者,超说明书用药,提供了PKPD理论依据。
关键词:  头孢哌酮钠舒巴坦钠  延时给药  血药浓度  药动学药效学  %T>MIC
DOI:10.13506/j.cnki.jpr.2020.10.014
基金项目:2016年台州市科技项目(No.1601KY29)
Clinical efficacy and economic evaluation of Cefoperazone and Sulbactam Sodium injection using micro-pumps for 3 hours
XIN Dongyi1,YU Xuhong2,FANG Fang3,XIN Xuejun4,XIE Juexing1,ZHU Qibing4,LIN Feng1,JIANG Neng5,DUAN Darong6,DING Ruliang1,ZHANG Zhijian1
(1.Taizhou First People's Hospital, Zhe jang, Taizhou 318020);1a: Surgical Department;1b:Clinical Pharmacy Department; 1c:Ophthalmology Department;1d:Central laboratory;2.The 305 Hospital of PLA, Clinical Pharmacy Department,Beijing;3.Chongqing Chinese traditional Medicine hospital,Clinical Pharmacy Department)
Abstract:
Objective Explore the difference antibacterial effect of Cefoperazone and Sulbactam Sodium in the same dose and different administration schemes.Methods The terminal drug concentration(c) of cefoperazone sodium and its pharmacokinetic and pharmacodynamic(PK/PD)% (T>MIC) were calculated after 0.5 h intravenous infusion and delayed administration (2 h, 3 h), and the clinical efficacy and pharmacoeconomic cost were evaluated.Results ① the 3-hour end-point drug concentration: the same dose (1g), delayed 2 h and 3 h groups were 140.3% (40.0/28.5) and 179.2% (51.1/28.5) of the 0.5 h group. ②The increase of antibacterial strength (T > MIC) was as follows: a. the same dose and different administration interval were given intravenously for 0.5h: Q8H and q6h groups increased by 50% and 100% compared with q12h group;b.At the same dose, different administration interval and different administration time: q12h group: delay time (2 h, 3 h), increased by 14%; 11.7%; Q8H group: increased by 13.8% and 20.9%;c.(q6h) (delay 2 h, 3 h) was 207% and 234.9% higher than that of Q12 h and 0.5 h, respectively;d.The same day dose (4.0 g) (%T > MIC) value: (1.0 g, q6h, delayed 2 h, 3 h), compared with (2.0g, q12 h, 0.5), increased by 50%-70%. ③The cost of medicine decreased by1/3: (1.0 g, 8 h, 2.0 h) (%T> MIC) = 61.2, compared with (2G, q12h, 0.5h), the daily dose of 4.0 g (% T>MIC = 60.0) was reduced by 1/3.Conclusion When increased the number of administration, combined with delayed administration of Cefoperazone and Sulbactam Sodium for 3 h, it can improved the antibacterial strength and saved the cost of medicine. It provided the theoretical basis of PKPD for patients with severe infection and off label medication.
Key words:  Cefoperazone and Sulbactam Sodium  Delayed administration  Blood concentration  Pharmacokinetics and pharmacodynamics  %T>MIC
今日访问量:2491    总访问量:55338934
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司